Health Policy Project

The Health Policy Project ended in 2016. Work continued under Health Policy Plus (HP+) until 2022.





According to the World Health Organization (WHO) and UNAIDS, Russia has one of the world’s most serious injecting drug use epidemics, which is fueling an explosion in HIV incidence. Injecting drug use accounts for 63 percent of all HIV cases and researchers estimate that there are up to 2 million persons who inject drugs (PWID)—of which, more than one-third are believed to be living with HIV.

Effective drug addiction treatment is a key component of HIV prevention programs for PWID in Russia. However, drug dependence treatment programs are limited and the only government-sanctioned pharmaceutical treatment for opiate addiction is naltrexone. Although largely used in Russia to treat alcoholics, recent data suggest that it may also be effective for treating drug addiction. While there is disagreement about its effectiveness for PWID, naltrexone is currently the only viable entry point to medication-assisted drug dependency treatment (MAT) in Russia.

What We Do

In Russia, the Health Policy Project (HPP) has worked to prevent the spread of HIV among PWIDs by expanding the knowledge base related to naltrexone and its treatment for drug dependence in the overall effort to reduce injecting drug use. HPP conducted research and compiling evidence to publish a report for Russian policymakers and experts on the efficacy of naltrexone, which will inform policy and clinical approaches in the development of an effective model to treat drug addiction.

Publications and Resources

Policy Analysis and Advocacy Decision Model for Services for People Who Inject Drugs
A collection of tools designed to help stakeholders create an inventory of country policies, analyze these policies against international best practices and human rights frameworks, assess policy implementation, and create a strategic advocacy plan.

Use of Naltrexone in the Treatment of Opioid Dependence in the Russian Federation: Situation Analysis
This situation analysis attempts to identify the perspectives, attitudes, and understanding of practitioners and civil society representatives on how naltrexone use could be used to address HIV and drug dependence in Russia.

   RSS Feed
Our Work
How We Help
Our Team
What We Do
Maternal Health
All Topics
AFR Region
AME Region
E&E Region
LAC Region
Software and Models
User Info
Privacy Policy
Site Map
Staff Intranet
The Health Policy Project is a five-year cooperative agreement funded by the U.S. Agency for International Development under Agreement No. AID-OAA-A-10-00067, beginning September 30, 2010. The project's HIV-related activities are supported by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). It is implemented by Futures Group, in collaboration with Plan International USA, Avenir Health (previously Futures Institute), Partners in Population and Development, Africa Regional Office (PPD ARO), Population Reference Bureau (PRB), RTI International, and White Ribbon Alliance for Safe Motherhood (WRA). The information provided on this Web site is not official U.S. Government information and does not represent the views or positions of the U.S. Agency for International Development or the U.S. Government.

Copyright © 2011 Futures Group. All Rights Reserved.2021,0,13,330286